Danaher Nears $10 Billion Masimo Acquisition

U.S. healthcare group Danaher Corp is reportedly nearing a deal to acquire medical technology company Masimo Corporation in a transaction valued at around $10 billion. The prospective deal has been reported by the Financial Times, citing people familiar with the matter, and could be announced as early as Tuesday if talks conclude successfully.

A roughly $10 billion price tag would represent a premium to Masimo’s recent market capitalization, which stood at about $7 billion as of last Friday. Masimo is a California-based med-tech firm best known for its medical monitoring devices, particularly in patient monitoring and blood oxygen measurement.

The potential acquisition would mark another significant deal for Danaher as it continues to expand its healthcare portfolio. Danaher operates across three main segments: Biotechnology, Life Sciences and Diagnostics, supplying equipment, consumables, software and services that support biological medicine development and clinical diagnostics.

Adding Masimo’s monitoring technologies would align with Danaher’s existing diagnostics and life sciences businesses, which serve hospitals, physicians’ offices, reference laboratories and other critical care settings. The deal would continue what has been described as Danaher’s aggressive history of dealmaking in healthcare.

Masimo has recently undergone organizational changes ahead of the reported transaction. The company completed an organizational realignment and sold its consumer audio business, steps that refocused the group more tightly on its core medical technology operations.

The med-tech firm also recently prevailed in a patent infringement case against Apple related to blood oxygen monitoring technology. Masimo’s legal victory in this intellectual property dispute underlines the value of its monitoring portfolio, which has been a key part of its positioning in the medical device market.

Reports indicate that, subject to final agreement, the Danaher–Masimo deal could be announced as early as Tuesday. While terms beyond the approximate $10 billion valuation have not been detailed, the indicated price reflects a notable premium to Masimo’s standalone market value.

Analyst commentary on Danaher referenced in recent research has focused on the company’s broader performance and outlook, with investment banks updating models following Danaher’s latest quarterly results. However, the reports related to the Masimo acquisition discussions do not specify how the potential transaction might affect these views.